Genomic Health, Inc. (NASDAQ:GHDX) CFO G Bradley Cole sold 6,471 shares of Genomic Health stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $57.08, for a total value of $369,364.68. The transaction was disclosed in a document filed with the SEC, which is available at this link.
G Bradley Cole also recently made the following trade(s):
- On Tuesday, June 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $51.46, for a total value of $257,300.00.
- On Tuesday, May 14th, G Bradley Cole sold 11,424 shares of Genomic Health stock. The shares were sold at an average price of $57.17, for a total value of $653,110.08.
GHDX traded down $1.81 during trading on Thursday, reaching $56.20. The company’s stock had a trading volume of 286,195 shares, compared to its average volume of 486,762. Genomic Health, Inc. has a 52-week low of $50.77 and a 52-week high of $92.18. The firm has a fifty day moving average of $54.74. The company has a market capitalization of $2.14 billion, a P/E ratio of 53.52 and a beta of 1.07. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.67 and a quick ratio of 5.67.
Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, May 7th. The medical research company reported $0.34 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.05. The company had revenue of $108.80 million for the quarter, compared to analyst estimates of $106.75 million. Genomic Health had a return on equity of 18.70% and a net margin of 10.35%. The firm’s revenue for the quarter was up 17.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.11) EPS. As a group, research analysts anticipate that Genomic Health, Inc. will post 1.46 EPS for the current year.
GHDX has been the topic of a number of analyst reports. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Beigene in a report on Thursday, June 20th. Needham & Company LLC set a $69.00 price objective on Genomic Health and gave the company a “buy” rating in a report on Wednesday, June 19th. BidaskClub raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 4th. ValuEngine lowered Valero Energy from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. Finally, Deutsche Bank set a $18.00 price objective on Commercial Metals and gave the company a “buy” rating in a report on Thursday, May 30th. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Genomic Health currently has an average rating of “Hold” and an average price target of $64.86.
Several large investors have recently made changes to their positions in GHDX. Norges Bank purchased a new stake in shares of Genomic Health during the 4th quarter worth approximately $20,975,000. Fiera Capital Corp purchased a new stake in shares of Genomic Health during the 1st quarter worth approximately $20,134,000. FMR LLC boosted its stake in shares of Genomic Health by 83.8% during the 4th quarter. FMR LLC now owns 550,627 shares of the medical research company’s stock worth $35,466,000 after acquiring an additional 251,085 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of Genomic Health by 1,336.7% during the 4th quarter. Two Sigma Investments LP now owns 209,592 shares of the medical research company’s stock worth $13,500,000 after acquiring an additional 195,004 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Genomic Health by 269.2% during the 1st quarter. Assenagon Asset Management S.A. now owns 267,410 shares of the medical research company’s stock worth $18,732,000 after acquiring an additional 194,988 shares in the last quarter. 95.54% of the stock is currently owned by institutional investors and hedge funds.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Featured Article: How to Invest in Marijuana Stocks
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.